查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413647

蛋白酪氨酸激酶抑制剂市场：按类型、应用和最终用户划分 - 2024-2030 年全球预测

Tyrosine Kinase Inhibitors Market by Type (BCR-ABL, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor), Application (Breast Cancer, Chronic Myeloid Leukemia, Lung Cancer), End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年蛋白酪氨酸激酶抑制剂市场规模为590.7亿美元，预计2024年将达到634.6亿美元，2030年将达到959.5亿美元，复合年增长率为7.17%。

蛋白酪氨酸激酶抑制剂的全球市场

主要市场统计
基准年[2023] 590.7亿美元
预测年份 [2024] 634.6亿美元
预测年份 [2030] 959.5亿美元
复合年增长率（%） 7.17%
酪胺酸激酶抑制剂市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估蛋白酪氨酸激酶抑制剂市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对蛋白酪氨酸激酶抑制剂市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-蛋白酪氨酸激酶抑制剂市场的市场规模与预测是多少？

在2-蛋白酪氨酸激酶抑制剂市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-蛋白酪氨酸激酶抑制剂市场的技术趋势和法律规范是什么？

4-蛋白酪氨酸激酶抑制剂市场主要供应商的市场占有率是多少？

进入5-蛋白酪氨酸激酶抑制剂市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症盛行率增加和标靶治疗的采用
      • 改善天然蛋白酪氨酸激酶抑制剂在医药配方中的使用
    • 抑制因素
      • 与抗药性发展和药物交互作用相关的限制
    • 机会
      • 持续研究提高蛋白酪氨酸激酶抑制剂的质量
      • 政府对蛋白酪氨酸激酶抑制剂的有利核准
    • 任务
      • 对蛋白酪氨酸激酶抑制剂肝毒性的担忧
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章蛋白酪氨酸激酶抑制剂市场：依类型

  • BCR-ABL
  • 表皮生长因子受体
  • 血管内皮生长因子受体

第七章蛋白酪氨酸激酶抑制剂市场：依应用分类

  • 乳癌
  • 慢性骨髓性白血病
  • 肺癌
  • 肾臟细胞癌

第八章蛋白酪氨酸激酶抑制剂市场：按最终用户

  • 居家护理
  • 医院
  • 专科诊所

第九章美洲蛋白酪氨酸激酶抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区蛋白酪氨酸激酶抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲蛋白酪氨酸激酶抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International
    • Bristol-Myers Squibb Company
    • Cipla Limited
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche
    • GlaxoSmithKline PLC
    • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • Johnson & Johnson Services, Inc.
    • Lupin Limited
    • Novartis AG
    • Pfizer Inc.
    • Spectrum Pharmaceuticals , Inc.
    • Steris Healthcare Pvt. Ltd.
    • Takeda Pharmaceutical Company Limited
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-B1685377971D

[181 Pages Report] The Tyrosine Kinase Inhibitors Market size was estimated at USD 59.07 billion in 2023 and expected to reach USD 63.46 billion in 2024, at a CAGR 7.17% to reach USD 95.95 billion by 2030.

Global Tyrosine Kinase Inhibitors Market

KEY MARKET STATISTICS
Base Year [2023] USD 59.07 billion
Estimated Year [2024] USD 63.46 billion
Forecast Year [2030] USD 95.95 billion
CAGR (%) 7.17%
Tyrosine Kinase Inhibitors Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Tyrosine Kinase Inhibitors Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Tyrosine Kinase Inhibitors Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Tyrosine Kinase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Cipla Limited, Eisai Co. Ltd., Eli Lilly and Company , F. Hoffmann-La Roche, GlaxoSmithKline PLC, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Johnson & Johnson Services, Inc., Lupin Limited, Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals , Inc., Steris Healthcare Pvt. Ltd., and Takeda Pharmaceutical Company Limited .

Market Segmentation & Coverage

This research report categorizes the Tyrosine Kinase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • BCR-ABL
    • Epidermal Growth Factor Receptor
    • Vascular Endothelial Growth Factor Receptor
  • Application
    • Breast Cancer
    • Chronic Myeloid Leukemia
    • Lung Cancer
    • Renal Cell Cancer
  • End-Users
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Tyrosine Kinase Inhibitors Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Tyrosine Kinase Inhibitors Market?

3. What are the technology trends and regulatory frameworks in the Tyrosine Kinase Inhibitors Market?

4. What is the market share of the leading vendors in the Tyrosine Kinase Inhibitors Market?

5. Which modes and strategic moves are suitable for entering the Tyrosine Kinase Inhibitors Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Tyrosine Kinase Inhibitors Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of cancer and increasing adoption of targeted therapy
      • 5.1.1.2. Improved use of natural tyrosine kinase inhibitors in medical formulations
    • 5.1.2. Restraints
      • 5.1.2.1. Limitations associated with resistance development and formulation interactions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to improve the quality of tyrosine kinase inhibitors
      • 5.1.3.2. Favorable government approvals for Tyrosine Kinase Inhibitors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with hepatotoxicity of tyrosine kinase inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Tyrosine Kinase Inhibitors Market, by Type

  • 6.1. Introduction
  • 6.2. BCR-ABL
  • 6.3. Epidermal Growth Factor Receptor
  • 6.4. Vascular Endothelial Growth Factor Receptor

7. Tyrosine Kinase Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Chronic Myeloid Leukemia
  • 7.4. Lung Cancer
  • 7.5. Renal Cell Cancer

8. Tyrosine Kinase Inhibitors Market, by End-Users

  • 8.1. Introduction
  • 8.2. Homecare
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Tyrosine Kinase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tyrosine Kinase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tyrosine Kinase Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AstraZeneca PLC
    • 13.1.2. Bayer AG
    • 13.1.3. Boehringer Ingelheim International
    • 13.1.4. Bristol-Myers Squibb Company
    • 13.1.5. Cipla Limited
    • 13.1.6. Eisai Co. Ltd.
    • 13.1.7. Eli Lilly and Company
    • 13.1.8. F. Hoffmann-La Roche
    • 13.1.9. GlaxoSmithKline PLC
    • 13.1.10. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    • 13.1.11. Johnson & Johnson Services, Inc.
    • 13.1.12. Lupin Limited
    • 13.1.13. Novartis AG
    • 13.1.14. Pfizer Inc.
    • 13.1.15. Spectrum Pharmaceuticals , Inc.
    • 13.1.16. Steris Healthcare Pvt. Ltd.
    • 13.1.17. Takeda Pharmaceutical Company Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. TYROSINE KINASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. TYROSINE KINASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. TYROSINE KINASE INHIBITORS MARKET DYNAMICS
  • FIGURE 7. TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. TYROSINE KINASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. TYROSINE KINASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. TYROSINE KINASE INHIBITORS MARKET SIZE, BY BCR-ABL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. TYROSINE KINASE INHIBITORS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. TYROSINE KINASE INHIBITORS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 10. TYROSINE KINASE INHIBITORS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. TYROSINE KINASE INHIBITORS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. TYROSINE KINASE INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. TYROSINE KINASE INHIBITORS MARKET SIZE, BY RENAL CELL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 15. TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. TYROSINE KINASE INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. TYROSINE KINASE INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM TYROSINE KINASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. TYROSINE KINASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 146. TYROSINE KINASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. TYROSINE KINASE INHIBITORS MARKET LICENSE & PRICING